C26H31NO10
Neat
517.53
76630-71-2; Naltrexone 3-glucuronide; beta-D-Glucopyranosiduronic acid, (5alpha)-17-(cyclopropylmethyl)-4, 5-epoxy-14-hydroxy-6-oxomorphinan-3-yl; RefChem:164470; Naltrexone-3-glucuronide; Morphinan, beta-D-glucopyranosiduronic acid deriv.; (2S, 3S, 4S, 5R, 6S)-6-[[(4R, 4aS, 7aR, 12bS)-3-(cyclopropylmethyl)-4a-hydroxy-7-oxo-2, 4, 5, 6, 7a, 13-hexahydro-1H-4, 12-methanobenzofuro[3, 2-e]isoquinolin-9-yl]oxy]-3, 4, 5-trihydroxyoxane-2-carboxylic acid; Naltrexone 3-O-Beta-D-Glucuronide (1.0 mg/ml in Methanol); DTXSID00997961; Naltrexone 3-O-?-D-Glucuronide; CHEBI:190029; NS00116974; Naltrexone 3-O-Beta-D-Glucuronide (1 mg/ml in Methanol); 17-(Cyclopropylmethyl)-14-hydroxy-6-oxo-4, 5-epoxymorphinan-3-yl hexopyranosiduronic acid; (2S, 3S, 4S, 5R, 6S)-6-[[(4R, 4aS, 7aR, 12bS)-3-(cyclopropylmethyl)-4a-hydroxy-7-oxo-2, 4, 5, 6, 7a, 13-hexahydro-1H-4, 12-methanobenzouro[3, 2-e]isoquinolin-9-yl]oxy]-3, 4, 5-trihydroxyoxane-2-carboxylic acid; (5alpha)-17-(Cyclopropylmethyl)-4 and 5-epoxy-14-hydroxy-6-oxomorphinan-3-yl beta-D-Glucopyranosiduronic Acid;
(2S, 3S, 4S, 5R, 6S)-6-[[(4R, 4aS, 7aR, 12bS)-3-(cyclopropylmethyl)-4a-hydroxy-7-oxo-2, 4, 5, 6, 7a, 13-hexahydro-1H-4, 12-methanobenzofuro[3, 2-e]isoquinolin-9-yl]oxy]-3, 4 and 5-trihydroxyoxane-2-carboxylic acid
InChI=1S/C26H31NO10/c28-13-5-6-26(34)15-9-12-3-4-14(35-24-19(31)17(29)18(30)21(37-24)23(32)33)20-16(12)25(26,22(13)36-20)7-8-27(15)10-11-1-2-11/h3-4,11,15,17-19,21-22,24,29-31,34H,1-2,5-10H2,(H,32,33)/t15-,17+,18+,19-,21+,22+,24-,25+,26-/m1/s1